{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "598 patients aged >70 years who underwent coronary revascularization"
      },
      "Intervention": {
        "score": 2,
        "evidence": "TAR group; 327, single ITA\u2009+\u2009SVG group"
      },
      "Objective": {
        "score": 1,
        "evidence": "Objectives: To assess whether total arterial revascularization (TAR) offers survival and freedom from major adverse cardiac or cerebrovascular events (MACCE) benefit"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The survival ( p =\u20090.410) and MACCE-free rates ( p =\u20090.494) over 5 years"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "428 patients remained (101, TAR group; 327, single ITA\u2009+\u2009SVG group)"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "100 patients in each group"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "HR\u2009=\u20090.74, 95% confidence interval (CI)\u2009=\u20090.44\u20131.22, p =\u20090.233"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  },
  "model": "gpt-4o"
}